Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

In reply.

Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM.

Oncologist. 2014 Mar;19(3):305-6. doi: 10.1634/theoncologist.2013-0395. Epub 2014 Feb 17. No abstract available.

2.

IMPACT Study: Targeted Prostate Cancer Screening.

Mikropoulos C, Eeles RA.

Oncologist. 2013;18(8):e28. doi: 10.1634/theoncologist.2013-0221. No abstract available.

3.

Resistance to "castration-resistant".

Luzzatto L.

Oncologist. 2014 Mar;19(3):305. doi: 10.1634/theoncologist.2013-0363. Epub 2014 Feb 17. No abstract available.

4.

Corticosteroids and prostate cancer: friend or foe?

Geynisman DM, Szmulewitz RZ, Plimack ER.

Eur Urol. 2015 May;67(5):874-5. doi: 10.1016/j.eururo.2014.08.008. Epub 2014 Aug 20. No abstract available.

PMID:
25151018
5.

Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.

Esch L, Schulz WA, Albers P.

Oncol Res Treat. 2014;37(9):492-8. doi: 10.1159/000365530. Epub 2014 Jul 11. Review.

PMID:
25231690
6.

Metastatic prostate cancer in 2015: The new and the old that is new again.

Graff JN, Beer TM.

Nat Rev Clin Oncol. 2016 Feb;13(2):73-4. doi: 10.1038/nrclinonc.2015.226. Epub 2015 Dec 31. No abstract available.

PMID:
26718107
7.

[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].

K├╝bler H, Miller K.

Urologe A. 2013 Nov;52(11):1517-8, 1520-1, 1524-6 passim. doi: 10.1007/s00120-013-3247-9. Review. German.

PMID:
24166056
8.

Intermittent androgen deprivation therapy: clarity from confusion.

Klotz L.

Eur Urol. 2013 Nov;64(5):731-3. doi: 10.1016/j.eururo.2013.06.038. Epub 2013 Jun 28. No abstract available.

PMID:
23866956
10.

Metastasis: Resistance fighters.

Savage N.

Nature. 2015 Dec 17;528(7582):S128-9. doi: 10.1038/528S128a. No abstract available.

PMID:
26672785
11.

Castration-resistant prostate cancer: adaptation or clonal selection? Insight from the EORTC 30891 trial.

Tombal B.

Eur Urol. 2014 Nov;66(5):839-40. doi: 10.1016/j.eururo.2013.11.047. Epub 2013 Dec 11. No abstract available.

PMID:
24341957
12.
13.

Substitution of anti-androgens and tegafur-uracil combination therapy for castration-resistant prostate cancer: results of a multi-center randomized phase II study.

Takahashi M, Kawabata R, Kawano A, Murakami Y, Sutou Y, Inai T, Akazawa S, Hamao T, Hayashi H, Fukawa T, Takemura M, Yamamoto Y, Yamaguchi K, Izaki H, Fukumori T, Kanayama H.

Int J Oncol. 2013 Sep;43(3):713-20. doi: 10.3892/ijo.2013.1997. Epub 2013 Jun 28.

PMID:
23817692
14.

The MAINSAIL trial: an expected failure.

Boccardo F.

Lancet Oncol. 2015 Apr;16(4):355-6. doi: 10.1016/S1470-2045(15)70058-6. Epub 2015 Mar 3. No abstract available.

PMID:
25743936
15.

Patient-related outcomes for metastatic prostate cancer.

Basch E.

Lancet Oncol. 2015 May;16(5):477-8. doi: 10.1016/S1470-2045(15)70171-3. Epub 2015 Apr 14. No abstract available.

PMID:
25888262
16.

The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer.

Moul JW.

Oncology (Williston Park). 2014 Aug;28(8):702-3, 722. No abstract available.

17.

What is the appropriate use of palliative docetaxel in castration-resistant prostate cancer?

Steineck G, Glimelius B.

Acta Oncol. 2013 Nov;52(8):1589-92. doi: 10.3109/0284186X.2013.821206. No abstract available.

PMID:
24102178
18.

Reply to K. Lu.

Fizazi K, Dreicer R.

J Clin Oncol. 2015 Oct 1;33(28):3222. doi: 10.1200/JCO.2015.62.4684. Epub 2015 Jul 27. No abstract available.

PMID:
26215954
19.

Reply to K. Lu.

Morris MJ.

J Clin Oncol. 2015 Oct 1;33(28):3222-3. doi: 10.1200/JCO.2015.62.4692. Epub 2015 Jul 27. No abstract available.

PMID:
26215948
20.

Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know.

Heidenreich A, Pfister D, Merseburger A, Bartsch G; German Working Group on Castration-Resistant Prostate Cancer (GWG-CRPC).

Eur Urol. 2013 Aug;64(2):260-5. doi: 10.1016/j.eururo.2013.05.021. Epub 2013 May 14. No abstract available.

PMID:
23706522

Supplemental Content

Support Center